tirzepatide cvot trial SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized We’re recruiting participants for Strength:4mg heart-support

tirzepatide cvot trial SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized We’re recruiting participants for Strength:4mg heart-support

We’re recruiting participants for the I‑BEGIN Study at Chelsea and Westminster Hospital and Imperial College London., Are you pregnant or planning pregnancy with:, ✅ Prior bariatric surgery, ✅ ...

Ok so that was the first big problem with GLP-1 agonists

heart-support

Strength:4mg

Which injection-site reactions does the post say are not typical and need medical attention